To develop a gene therapy that would selectively kill prostate cancer cells while sparing normal cells, we have constructed lentiviral vectors that contain a therapeutic gene with a short DNA sequence in the 5 0 -untranslated region (UTR) that is recognized by the translation initiation factor, eIF4E, which is often overexpressed in malignant cells. Infection of cancer (LNCaP, PC-3M, DU145, and MCF-7 cells) and noncancer cell lines (BPH-1, 267-B1, Plat-E, and Huvec-c cells) with lentivirus having a CMVpromoter and EGFP reporter resulted in high levels of EGFP expression in all cells, whereas, inclusion of the eIF4E UTR recognition sequence restricted high expression to cancer cells and Plat-E cells, which also express substantial levels of eIF4E. Infection of the cells with lentiviral vectors having this UTR in front of the HSV thymidine kinase suicide gene resulted in differential sensitivity to the killing effects of ganciclovir, with at least 100-fold more drug required to kill noncancer cells than cancer cells. Furthermore, in experiments where the CMV promoter was replaced by the prostate-specific ARR 2 PB promoter, the killing effects of ganciclovir were restricted to prostate cancer cells and not seen in nonprostate cancer cells. Our results indicate that combined translational regulation, by incorporation of an eIF4E-UTR recognition sequence into a therapeutic gene, together with transcriptional regulation with a prostate-specific promoter, may provide a means to selectively destroy prostate cancer cells while sparing normal prostate cells.
Introduction
Prostate cancer remains the second leading cause of cancer death in men largely due to malignant progression to advanced, hormone-refractory and metastatic disease for which there are few treatment options available. 1, 2 To address the issue of new treatments for advanced disease, several strategies have been proposed to develop a viralbased systemic gene therapy employing a variety of prostate-specific gene promoters, such as those for prostate-specific antigen (PSA), 3 prostate-specific membrane antigen (PSMA) 4 , and probasin (PB), 3, 5 for directing the expression of a cytotoxic gene exclusively in prostate cells. The utility of this approach for targeting has been demonstrated in many preclinical studies of prostate cancer with some having entered into Phase I clinical trials. 6 A few of these clinical protocols have demonstrated some anticancer activity in using, for example, viral-mediated transfer of HSV-TK plus GCV to treat prostate cancer. 7 Although there are still a number of problems to be solved concerning systemic delivery and specific targeting, the development of a clinically relevant gene therapy for prostate cancer shows great potential.
Overexpression of the mRNA cap-binding protein, eIF4E, is characteristic of many cancers and may in itself lead to increased cell proliferation, suppression of apoptosis, and other phenotypic changes associated with malignant transformation. 8 Several studies have indicated that high levels of eIF4E result primarily in enhanced translation of a few select mRNAs including growth factors and other proteins known to be associated with malignant progression and metastases, such as cyclin D1, VEGF, FGF-2, and matrix metalloprotease 9. [8] [9] [10] [11] The secondary structure in the 5 0 -untranslated region (UTR) of these mRNAs normally acts to repress their translation, but in the presence of sufficient eIF4E/eIF4F complex, the UTR structure is unwound and the mRNA efficiently translated. 12 DeFatta et al. 13 placed the UTR from FGF-2 in front of herpes simplex virus thymidine kinase (HSV-TK) cDNA and in a series of transfection experiments showed expression of this enzyme and subsequent cell kill by the prodrug ganciclovir (GCV) in breast cancer cells, but not in two lines of normal cells. These and related studies 13, 14 suggested that incorporation of this UTR sequence, which is recognized by eIF4E, into a viral vector or similar delivery system could provide the basis for developing a gene therapy to selectively target cancer cells while sparing normal cells. Predictably, the loss of PTEN expression, which is often observed in advanced prostate cancers, results in deregulation of the AKT-signaling pathways, and subsequently leads to an increase in eIF4E expression and/or activation. [15] [16] [17] In the present study, we sought to combine the potential for cancer cell targeting by incorporating the FGF-2 UTR sequence recognized by eIF4E into a reporter or a therapeutic gene with specific prostate tissue targeting by using a PB-derived promoter (ARR 2 PB). 5, 18 Although well documented in the case of other solid tumors, 8 we showed elevated expression of eIF4E in human prostate cancer biopsies through analysis of human prostate cancer tissue microarray. We initially tested the relative expression of enhanced green fluorescent protein (EGFP) in cancer and noncancer cells infected with a lentiviral CMV construct with the UTR sequence in front of an EGFP reporter. To test for preferential prostate cancer cell killing, the EGFP reporter was swapped for HSV-TK in the lentiviral constructs and compared in the context of either a CMV promoter or the prostate-specific ARR 2 PB promoter. The results indicated that inclusion of this UTR sequence in front of a therapeutic gene limited expression of these proteins and subsequent cell kill to cancer cells. Furthermore, replacement of the CMV promoter with the ARR 2 PB promoter further restricted expression to prostate cancer cells alone.
Materials and methods

Cell lines and culture conditions
LNCaP, MCF-7, DU145, 267B1, and Huvec-c cell lines were obtained from American Type Culture Collection (ATCC) (Manasas, VA, USA). PC-3M cells were generously given by Dr Charles Myers (University of Virginia), BPH-1 cells were a gift from Dr Simon Hayward (Vanderbilt University), and Plat-E cells were kindly provided by Dr T Kitamura (University of Tokyo). 19 The cell lines 293T, LNCaP, MCF-7, and BPH-1 were grown in RPMI 1640 supplemented with 5% fetal bovine serum (FBS) and antibiotics (penicillin and streptomycin). PC-3M, Plat-E, and MM3MG (TK) 13 were grown in DMEM supplemented with 5% FBS and antibiotics. Huvec-c cells were grown in Ham's F12K medium (ATCC) supplemented with 2 mM L-glutamine, 0.1 mg/ml heparin, 0.03-0.05 mg/ml endothelial cell growth supplement (ECGS), and 10% FBS. The 267B1 cell line was grown in BRFF-HPC1 medium (AthenaES). All cells lines were propagated in a 5% CO 2 environment, at 371C.
Plasmid construction
The 5 0 -UTR (619 bp) of rat FGF-2 cDNA was obtained from plasmid rFGF(T3) at XhoI-BamHI sites as previously described 20 and cloned into plasmid pEGFP-N1 (Clontech) at corresponding sites. The fragment was then excised from pEGFP-N1 using BglII-BamHI sites and inserted at a single BamHI site of the previously used control plasmid pHR 0 -CMV-EGFP, 21 creating Lv-CMV-U-EGFP. The orientation and position of gene insertion was confirmed by sequencing.
Polymerase chain reaction (PCR) was used to create lentiviral vectors expressing the suicide gene HSV thymidine kinase (TK) gene. 22 The B1.2 kb TK was obtained by PCR (941C for 2 min, 941C for 30 s, 601C for 1 min, 721C for 1 min, 35 cycles from the second step, then 721C for 7 min) using primers with flanking BamHI and XhoI sites (5 0 TCGGGATCCCGTATGGCTTCGTACC and 5 0 TGTCTCG-AGTGTTTCAGTTAGCC) and plasmid BK-TK as the PCR template. 13 The PCR product was digested with BamHI and XhoI, purified and inserted into complementary sites of pHR 0 -CMV-EGFP, creating the Lv-CMV-TK plasmid.
The EGFP gene was removed from plasmid pHR 0 -CMV-EGFP at BamHI-KpnI and replaced by a linker strand of DNA encoding for multiple cloning sites (-BamHI-XhoI-SpeI-KpnI), creating a medium plasmid. The 3.6 kb UTK fragment was released from BK-UTK 13 at XhoI-SpeI sites and cloned into the medium plasmid to create Lv-CMV-UTK. The Lv-ARR 2 PB-EGFP, Lv-ARR 2 PB-TK, and Lv-ARR 2 PB-UTK were developed by replacing the CMV promoter with ARR 2 PB pro moter. 5 In total, seven plasmids were used for this study as represented in Figure 1 .
Lentiviral vector preparation, infection, and EGFP assay
The method for lentiviral preparation used in this study was as described previously. 21 Briefly, 1.5 Â 10 6 293T cells were seeded onto10-cm plates and co-transfected, using the calcium phosphate precipitation method (Promega Profection Mammalian Transfection Systems), with 10 mg of transfer plasmids, 10 mg of pCMVDR8.2, and 5 mg of pMD.G for 12-16 h in unconditioned DMEM medium. After the transfection period, the medium was replaced with DMEM containing 5% FBS and antibiotics. The vector-conditioned medium was collected at 24 h intervals (for a maximum of 4 days), passed through a 0.45 mm filter to remove cellular debris, and then stored at À701C for future use. Lentiviral concentrations were determined using a p24 viral protein ELISA. 21 Viral vectors were also measured by counting the number of EGFP-positive cells 72 h postinfection of 2 Â 10 4 LNCaP cells per well in 24-well plates. To concentrate the viral vectors, conditioned medium stocks were ultracentrifuged at 50 000 g for 90 min using an SW-28 rotor. The virus pellets were resuspended in serum-free DMEM and aliquoted for later use.
Lentiviral vector infections were performed as described previously. 5 Briefly, cells were seeded in 24-well plates at a density of 1 Â 10 4 cells/well in 0.5 ml of medium or in six-well plates at a density of 1 Â 10 5 cells/well in 2 ml of medium. After 24 h, virus stocks were added to the cell cultures at a multiplicity of infection (MOI) of 30. Media were changed 16 h post-infection and EGFP-positive cells were counted under UV microscopy 48 h post-infection. The cells infected with EGFP expression virus and control cells were then trypsinized, washed with 1 Â PBS, and suspended in 1 ml of 1 Â PBS. Samples were analyzed with a Becton Dickinson FACScalibur flow cytometer using Cell Quest software, and data were analyzed with fit mode on WinMDI version 2.8.
Determination of eIF4E of cell lines and the HSV-TK activity by Western blot Levels of eIF4E, b-actin, and HTK in tumor and nontumor cell lines were assayed using Western blotting techniques as before. 23 Briefly, cells were lysed with RIPA buffer (10 mM Tris-HCl (pH 8.2), 1% deoxycholate, 0.4% EDTA) for 30 min on ice. Cell debris was removed by centrifugation at 12 000 g for 10 min and the resulting supernatant was assayed for protein concentration using BCA Protein Assays (Pierce). In all, 20 mg of protein lysate, together with sample buffer, were run on 10% sodium dodecyl sulfate polyacrylamide gel (SDS-PAGE). After SDS-PAGE, the separated proteins were transferred to Immobilon-P transfer membranes (Millipore). The membranes were blocked with 5% skim milk in trisbuffered saline (TBS) containing 0.05% tween-20 and probed with 1:1000 rabbit polyclonal anti-eIF4E antibody (Cell Signalling), 1:500 anti-HTK (a gift from Dr William C Summers, Yale University), or 1:500 anti-b-actin antibody (Sigma), followed by 1:2000 polyclonal goat anti-rabbit antibody conjugated to horseradish peroxidase (Bio-Rad). The corresponding eIF4E, HTK, and b-actin bands were detected by ECL (Amersham Biosciences) and band intensities were quantified using Quantity One (Bio-Rad).
Ganciclovir (GCV) cytotoxicity and cell viability assay Tumor and nontumor cells were seeded in 24-well plates at a concentration of 2 Â 10 4 cells/well in 0.5 ml of Figure 1 Structure of lentiviral transfer plasmid used in these studies. The EGFP gene of control vector Lv-CMV-EGFP(1) was replaced by TK gene to develop Lv-CMV-TK(3). The 5 0 -UTR was inserted in front of EGFP and TK to develop Lv-CMV-U-EGFP(2) and Lv-CMV-UTK (4). CMV promoters of vector (1), (3), and (4) were replaced by ARR 2 PB promoter to create Lv-ARR 2 PB-EGFP(5), Lv-ARR 2 PB-TK(6), and Lv-ARR 2 PB-UTK (7).
Cancer and prostate-specific targeting D Yu et al medium. After 24 h, cells were infected with lentiviral vectors CMV-TK/UTK, ARR2PB-TK/UTK, and the control vector CMV-EGFP. At 48 h postinfection, GCV was added at concentrations ranging from 0.1 to 100 mM (Sigma). Cell viability was determined using the Hyclone cell viability assay, 5 days after addition of GCV. Briefly, cells were washed with and suspended in PBS, an equal volume of 0.4% Trypan blue was added to cell suspensions, and the cells were incubated for 1-2 min. The number of unstained cells and total cells was determined following procedures of hemocytometer counting. The percentage viability was determined by dividing the number of unstained cells by the total number of cells counted and the quotient multiplied by 100%. Each experiment was performed in triplicate before data were analysed. An estimation of the GCV concentration equivalent to 50% cell viability was determined through extrapolation on cell death curves.
Immunohistochemical staining of prostate tissue arrays for eIF4E
Prostate tissue samples were obtained from the tissue bank of the Department of Pathology at Vancouver General Hospital. Prostate tissue samples were all obtained from radical prostatectomy specimens and were chosen for their representation of various Gleason grades (G2-G5). Patient demographics, pathology number, paraffin block label, diagnosis, and clinical correlative data were entered in a central database and appointed to the tissue microarray map. Cancer sites in donor paraffin blocks were identified by a pathologist (LF) using matching H&E reference slides and the tissue microarray was constructed using a tissue puncher (Beecher Instruments, Silver Spring, MD, USA). Quadruplicate cores (n ¼ 272), each 0.6 mm in diameter, from 68 individual cancer patients were arrayed in recta-linear pattern. Sections were deparaffinized by xylene and rehydrated through 100, 90, and 70% ethanol washes, and then transferred to the 0.02% Triton X for permeabalization. Slides in citrate buffer (pH ¼ 6) were heated in the steamer for 30 min. After cooling for 30 min and 3 Â 5 min wash in PBS, the slides were incubated in 3% H 2 O 2 for 10 min. Slides were transferred to 3% BSA for 30 min and then incubated at 41C overnight with anti-eIF4E antibody (Cell Signaling Technology Inc, Beverly, MA, USA) at a working dilution of 1/50 in 1% BSA. The following day unbound primary antibody was washed off extensively with PBS and the LSAB þ kit (Dako) was used as the detection system. The Chromogen Nova-red (Laboratories) was applied for 2 min and counterstaining was done with Hematoxylin (Vector Laboratories). After rehydration with ethanol, the slides were sealed with coverslips using a xylene-based mounting media, Cytoseal (Stephen Scientific). Negative control slides were processed in a manner identical to that above, with the substitution of 1% BSA for the primary antiserum. Photomicrographs were taken through a Leica DMLS microscope coupled to a digital camera (Photometrics CoolSNAP, Roper Scientific, Inc.) and corresponding computer software. The staining intensity (0-3) was graded by a pathologist (LF) representing the range from little staining to heavy staining. All comparisons of staining intensity and percentages were made at Â 200 magnification.
RNA isolation and real-time RT-PCR
LNCaP and BPH-1 cells were infected with lentiviral vectors Lv-CMV-EGFP and Lv-CMV-U-EGFP as before. Medium was changed at the 2nd and 4th day after infection. At day 5 of infection, cells were washed three times with PBS and total RNA was isolated using Trizol Reagent (Invitrogen). First-strand cDNA was synthesized using 1 mg of total RNA in a 20 ml reverse transcriptase reaction mixture using Superscript II transcription reverse transcription reagents (Invitrogen). Oligonucleotide primers for EGFP gene (5 0 -CAAGGTGAACTTCAA GATCC and 5 0 -CCAGCAGGACCATGTGATCG) and housekeeping b-actin gene were designed for real-time PCR using the Primer Express 2.0 software (Applied Biosystems, Foster City, CA, USA). All real-time PCR reactions were performed using the ABI prism 7000 Sequence Detection System (Applied-Biosystems) in the presence of SYBR-green in a 25 ml mixture containing 1/20 volume of cDNA preparation. The optimization of the real-time PCR reaction was performed according to the manufacturer's instructions and protocols. Real-time quantitations were performed using the fold change method as recommended by the manufacturer of the ABI prism 7000 Sequence Detection System. Relative quantitation of gene expression was performed using the fold change method as described in Talaat et al. 24 Briefly, the normalized value for all amplification runs was calculated by subtracting threshold cycle (C t ) values of the target genes from those of b-actin, as the endogenous control. The standard curve for each gene was constructed from the three serially diluted samples in duplicate, starting with the neat cDNA and diluted to 1:5 and 1:25. The relative levels of transcription were determined by comparison of C t values between the experimental group and the control to calculate fold changes.
Results
Expression of eIF4E in human prostate cancers using tissue microarrays Although well documented in the case of other solid tumors (for review see De Benedetti and Graff 8 ), we sought to determine whether elevated expression of eIF4E is a characteristic of human prostate cancers. Accordingly, we analyzed a human prostate cancer tissue microarray composed of 272 tumor cores obtained in quadruplicate from 68 cancer patients. Immunological staining intensity for eIF4E protein was scored visually by a pathologist on a scale from 0 to 3, with 0 indicative of no staining and 3 indicating very intense staining. A representative immunohistology picture of eIF4E staining in a G3-G4 Gleason grade core is shown in Figure 2 . Where detected, eIF4E protein was focally positive and Cancer and prostate-specific targeting D Yu et al confined mainly to the cytoplasm with occasional nuclear staining observed. In all the tumors, o3% were found to be negative for eIF4E, whereas 54% showed moderate to strong staining and 43% were weakly positive. While there was no significant difference (Mann-Whitney test) in the median staining intensities of eIF4E protein with different Gleason grades (Table 1 ), a major difference in intensities was seen when comparing tumor cell foci with adjacent normal cells. In 82% of the patient samples, the adjacent normal cells were either negative (45%) or weakly positive (37%). Hence, similar to expression patterns observed in other solid tumors, most prostate cancers are associated with enhanced expression of eIF4E compared to non-neoplastic prostate tissue.
Expression of eIF4E in cancer and noncancer prostate cell lines Western analyses were performed to determine relative expression levels of eIF4E in prostate cancer cell lines compared to nontumorigenic prostate cell lines. Protein extracts from four tumorigenic cancer lines, LNCaP, DU145 and PC-3M prostate cancer cells as well as MCF-7 breast cancer cells, were probed with antibodies to eIF4E and b-actin. The Western blots were scanned and compared to those obtained using proteins from noncancer, nontumorigenic prostate (BPH-1 and 267-B1 cells) and nonprostate (Plat-E and Huvec-c) cell lines. As shown in Figure 3 , LNCaP, MCF-7, DU145, and Plat-E embryonic kidney cells displayed relatively high expression of eIF4E protein, whereas PC-3M, BPH-1, 267-B1, and Huvec-c endothelial cells had the lowest levels. After immunostaining for eIF4E of a prostate cancer tissue microarray (272 tumor cores from 68 patients), the samples were assessed for staining intensity (0-3) and Gleason grade (2-5) by a pathologist. Since the reduced EGFP fluorescence in Lv-CMV-U-EGFP infected nontumor cells could be caused by difference of transcriptional efficiency between tumor and nontumor cells, quantitative real-time PCR was performed in both LNCaP and BPH-1 cells infected with Lv-CMV-U-EGFP or Lv-CMV-EGFP. The mean ratio of EGFP transcript levels after normalizing with actin for each sample between U-EGFP and EGFP in BPH-1 and LNCaP cells was 17.270.6 and 2.1770.32, respectively. Thus, the levels of transcripts for U-EGFP were actually higher than EGFP in both cell lines, suggesting that the lower protein level of EGFP in BPH-1 cells was not due to difference in transcriptional efficiency between the two cell lines.
Differential cell killing using lentiviral vectors expressing thymidine kinase Differences in expression of EGFP in cells infected with lentiviral vectors containing the eIF4E-recognized UTR sequence suggest that this type of targeting approach may be used as part of a viral-based gene therapy to efficiently kill prostate cancer cells while sparing most noncancer cells. Previously, this UTR was linked in an expression plasmid construct (BK-shuttle vector) to herpes simplex thymidine kinase (HSV-TK), and in transfection experiments was shown to enhance the killing effects of the prodrug ganciclovir (GCV) in human breast cancer cells compared to a normal breast cell line. 13 Viral-mediated transfer of HSV-TK gene has been shown by several investigators to confer sensitivity to nucleoside analogs such as GCV in a variety of tumor cells. 25 In the present study, we swapped the EGFP-reporter component in the Lv-CMV-U-EGFP and Lv-CMV-EGFP vectors for HSV-TK creating Lv-CMV-UTK and Lv-CMV-TK, respectively (Figure 1 ), which together with Lv-CMV-EGFP controls were then used to infect (MOI ¼ 30) the same panel of prostate cancer and noncancer cells described above.
Proteins were extracted at day 4 postinfection and analyzed by Western blotting for expression of HSV-TK relative to b-actin levels. As can be seen in Figure 5a , all the cells infected with Lv-CMV-TK express high levels of HSV-TK relative to MM3MG(tk) cells, a breast cell line that stably expresses this enzyme. 13 By comparison, after treatment with Lv-CMV-UTK, only those cells that express moderate to high amounts of eIF4E displayed substantial HSV-TK expression (Figure 5b ). In these cells, the amount of HSV-TK relative to b-actin was slightly less after infection with Lv-CMV-UTK (Figure 5c ).
The dose-response curves to GCV after infections with Lv-CMV-TK, Lv-CMV-UTK or Lv-CMV-EGFP (controls) are shown in Figure 6 . In LNCaP prostate cancer cells, 50% cell viability was seen at a GCV concentration of B0.01 mM after infection with either TK-expressing vector or UTK-expressing vector, whereas infection with EGFP control virus did not appreciably sensitize the cells to GCV at any concentration (e.g. 75% cell viability at 100 mM GCV). PC-3M prostate cancer cells were somewhat less sensitive to the drug (50% cell viability at 0.09 and 0.6 mM GCV, respectively), although the viability curves for both Lv-CMV-TK and Lv-CMV-UTK infections were similar. By comparison, MCF-7 breast cancer cells were generally less sensitive to the killing effects of GSV (50% cell viability at 6.8 mM GSV) irrespective of what TK-expressing agent was used in the experiments. Since infected MCF-7 cells expressed high levels of TK ( Figure 5 ), the difference in sensitivity is likely not due to transcriptional or translational efficiencies, but rather some intrinsic cell differences. Overall in cancer cells treated with either Lv-CMV-TK or Lv-CMV-UTK, there was no significant difference in cell viability (t-test, P40.05), whereas both treatment groups differed significantly from the Lv-CMV-EGFP infected controls (Po0.05) at GCV concentrations 40.01 mM for the prostate cancer lines and 41 mM for the breast cancer line.
Both noncancer prostate cell lines (BPH-1 and 267-B1) displayed similar sensitivity to GCV when infected with Lv-CMV-TK, but had EGFP-control levels of GCVinduced cell killing using the Lv-CMV-UTK vector. A similar pattern was also observed in Huvec-c cells, another noncancer line, whereas Plat-E embryonic kidney cells, which express relatively high levels of eIF4E, displayed a lesser degree of sensitivity to low concentrations of GCV (o1 mM) than might be predicted. Clearly, other factors can influence the relative effectiveness of GCV in a given cell line. Similar results were seen using an MTS assay (data not shown) for measuring cell death with GCV treatment on LNCaP and BPH1 cell lines. In summary, with the noncancer cell lines, there was no significant difference (t-test, P40.05) in the cell viability after treatment of either Lv-CMV-EGFP or Lv-CMV-UTK infected cells at concentrations of o10 mM GCV, whereas Lv-CMV-TK-infected cells had a much greater sensitivity to GCV (t-test, Po0.05) at different threshold concentrations (40.01 mM for BPH-1 and 267-B1 cells, 40.1 mM for Plat-E cells, and 41 mM for Huvec-c cells).
Targeting prostate cancer cells using lentiviral vectors expressing thymidine kinase under a prostate-specific promoter We previously reported that a lentiviral vector (Lv-ARR 2 PB-EGFP) containing EGFP driven by a probasinderived promoter, ARR 2 PB, 18 allowed for in vitro and in vivo prostate-specific expression of EGFP. 5 In the present study, we sought to determine whether inclusion Cancer and prostate-specific targeting D Yu et al of the 5 0 UTR recognized by eIF4E would have any influence on the prostate-specific expression dictated by the ARR 2 PB promoter. Two lentiviral vectors, Lv-ARR 2 PB-TK and Lv-ARR 2 PB-UTK, were created and used to infect LNCaP prostate cancer cells and MCF-7 breast cancer cells. Cells were infected with these vectors or with Lv-ARR 2 PB-EGFP controls and tested as above for GCV toxicity. In experiments with LNCaP cells (Figure 7 ), some cell kill was observed at a concentration of 0.1 mM GCV, with 50% cell viability seen at a concentration of 0.3 and 0.4 mM GCV following infection with Lv-ARR 2 PB-TK or Lv-ARR 2 PB-UTK, respectively. Cells treated with the control virus were largely resistant to the killing effects of GCV. The decreased GCV sensitivity in LNCaP cells compared to experiments with Lv-CMV-TK or Lv-CMV-UTK is in keeping with the relative promoter strength of ARR 2 PB vs CMV. 5 However, there was no apparent impact of the 5 0 UTR on GCV sensitivity in the context of a prostate-specific promoter. When similar experiments were performed using MCF-7 breast cancer cells (Figure 7 ), there were no obvious differences in GCV dose responses using any of the lentiviral vectors, with all being resistant to this drug. Thus, insertion of the 5 0 UTR sequence did not influence the prostate-specific expression of the ARR 2 PB promoter.
Discussion
As the most frequently diagnosed, potentially lethal cancer in men, prostate cancer is only curative in patients with localized tumors that are amenable to surgical or radiation ablation. 1, 26 The fact that it metastasizes at a relatively early stage and that there is no curative therapy for metastatic prostate cancer accounts for it being one of the leading cancer killers of males. 27 The development of an effective gene therapy to treat prostate cancer has largely focused on the goal of targeted expression of therapeutic genes specifically to prostate tumors and metastases. To this end, several viral-based strategies have been devised and tested to target prostate cancer cells using prostate-specific gene promoters for restricted expression of cytotoxic proteins such as HSV-TK. [3] [4] [5] 21 In the present study, we investigated a novel combination of cancer cell targeting at the protein translational level with prostate tissue targeting at the transcriptional level in the context of a lentivirus vector to determine whether differential targeting and killing of cancer vs noncancer cells could be achieved while still retaining prostate specificity.
The eukaryotic initiation factor (eIF)4E is the ratelimiting subunit of the eIF4F complex composed of eIF4E, eIF4A, and eIF4G. 28 Functioning as the Cancer and prostate-specific targeting D Yu et al cap-binding protein, eIF4E is critically important for the activity of the initiation process of translation by unwinding excess secondary structure in the 5 0 -UTR of mRNA. 10, 29 Normally, low levels of eIF4E create a situation of competition among different mRNA species such that mRNAs with long, G/C-rich 5 0 -UTRs are outcompeted for binding to ribosomes by other mRNAs and hence are translated less efficiently. 30 However, high levels of eIF4E are often found in many cancers, enabling increased translation of growth factors and other oncogenic proteins that support the malignant phenotype. [8] [9] [10] [11] 31 Conversely, reduction of eIF4E cellular levels through any means, including treatment with specific antisense RNA or increasing the expression of inhibitory 4E-binding proteins by administration of the mTOR inhibitor, rapamycin, results in an antitumor effect. 32, 33 Taking advantage of prevalent overexpression of eIF4E in cancer cells and its precise recognition of highly structured 5 0 -UTRs, DeFatta et al. A necessary prerequisite for the application of this form of tumor targeting to prostate cancer is to ensure that most prostate tumors express high levels of eIF4E protein (Figure 2 ). In examining multiple tumor cores from 68 patients, we found that while most adjacent normal tissue showed weak or absent immunological staining for eIF4E, 97% of tumors displayed positive staining ranging from strong to moderate (54%) to weak intensity (43%). However, there was no statistically significant relationship (Mann-Whitney test) between the relative amount of eIF4E detected and Gleason grade (Table 1) , an established index of prostate cancer prognosis and differentiation. 34 Nevertheless, as with most other solid tumors, increased expression of eIF4E is associated with human prostate cancers. This relationship was also seen in prostate cancer cell lines (LNCaP and DU145), which by Western blot analyses were shown to express much higher levels of eIF4E protein than noncancerous cell lines of prostate origin (BPH-1 and 267-B1) (Figure 3 ).
Beta-actin
HSV-TK
To test for bioactive eIF4E, lentivirus constructs were created with or without the FGF-2 5 0 UTR recognized by eIF4E placed in front of an EGFP reporter ( Figure 1 ). As before, 5 an MOI of 30 ensured that virtually 100% of the cells were infected. In the absence of the FGF-2 UTR, all lentiviral-infected prostate cells showed high levels of EGFP fluorescence, whereas in its presence, only prostate cancer cells displayed strong fluorescence (Figure 4) . Real-time PCR measurements indicated that the levels of transcripts for U-EGFP were actually higher than EGFP in both cell lines, suggesting that the lower protein level of EGFP in BPH-1 cells was not due to difference in transcriptional efficiency between the two cell lines. In general, the fluorescence signals were in good agreement with the relative levels of eIF4E found in all the cell lines tested. Although outside the scope of this present paper, the Lv-CMV-U-EGFP vector or derivatives could potentially provide an agent for cancer detection based on a fluorescent signal elicited by the occurrence of high levels of eIF4E in cancer cells.
Encouraged by the cancer-related differences in expression levels of EGFP, we modified our lentiviral vectors such that the reporter was switched with the HSV-TK gene to create a viral-based suicide gene therapeutic (Figure 1) . In an earlier study, the efficacy of using the FGF-2 UTR to regulate translation of HSV-TK in order to differentially sensitize breast cancer cells to the killing effects of GCV had been shown in transfection experiments. 13, 14 As one of the most frequently used suicide gene, HSV-TK phosphorylates the prodrug GCV creating a toxic form that effectively inhibits DNA synthesis leading to cell death. 35, 36 Since human prostate cancers are very slow in growing with usually o6% of the tumor population undergoing cell division at any given time, 37 lentivirus, which are capable of infecting both dividing and nondividing cancer cells and which have been shown to achieve long-term gene expression both in vitro and in vivo, are an extremely effective gene delivery system for this cancer. 21, 38 Using lentiviral vectors expressing HSV-TK under the translational control of the eIF4E-recognized UTR, we found a pattern of gene expression analogous to that seen in experiments with the EGFP reporter with the highest levels of HSV-TK protein seen in prostate cancer cells ( Figure 5 ). In general, the levels of HSV-TK protein expression reflected the extent of cell kill observed when the cells were treated with GCV ( Figure 6 ). LNCaP prostate cancer cells were the most sensitive to GCV concentrations with an apparent 50% viability at B0.01 mM after infection with either Lv-CMV-TK or Lv-CMV-UTK. By comparison, the two noncancer prostate cell lines had 50% viability in a similar range (0.01-0.1 mM GCV) only after infection with viruses not having the modified UTR. These results suggest that inclusion of the FGF-2 5 0 UTR may provide a means to target prostate cancer cells while minimizing damage to normal prostate cells.
Not all cells showed a direct relationship between eIF4E levels and subsequent response to therapy. MCF-7 Figure 7 Effects of a prostate-specific promoter on cell killing using the HSV-TK/GCV system. LNCaP and MCF-7 cells were infected with Lv-ARR 2 PB-TK, Lv-ARR 2 PB-UTK, or Lv-ARR 2 PB-EGFP (control) and treated with different concentrations of GCV (0.01-100 mM) 48 h later. The percent cell viability was measured using dye exclusion assay at day 5 after GCV was added. Results are shown as mean7s.e.m. (n ¼ 3).
Cancer and prostate-specific targeting D Yu et al breast cancer cells express high levels of eIF4E and HSV-TK, but their response to GCV is somewhat blunted (50% viability B7 mM GCV) as compared to the prostate cancer cell lines. More in keeping with the correlation between eIF4E levels and expression of HSV-TK, lentiviral-infected Huvec-c endothelial cells have a relatively low concentration of eIF4E protein and a similar pattern of response to GCV as seen in other noncancer cells, whereas Plat-E embryonic kidney cells express relatively high levels of eIF4E protein and are more sensitive to the killing effects of GCV after infection with Lv-CMV-UTK ( Figure 6 ). Whether there is a large subset of noncancer 'normal' cells that express high levels of eIF4E protein is unknown, but it does raise a cautionary that unrestricted exposure to a gene therapeutic such as Lv-CMV-UTK may have a negative impact on some normal tissues.
To address the issue of reducing potential cell toxicity to normal tissues, we further modified our lentivirus constructs to ensure that expression of HSV-TK was restricted to prostate cancer cells. Previously, we demonstrated that we could differentially target in vitro or in vivo expression of an EGFP reporter in a lentivirus to prostate cancer cells by using a probasin-derived gene promoter, ARR 2 PB. 5, 18 While the activity of this promoter is greatly enhanced by androgens through direct binding of the androgen receptor, the presence of an androgen receptor is not sufficient in itself to dictate prostate-specific expression. However, it is interesting to note that most prostate tumors, even those that are functionally androgen independent, seem to possess a constitutively active form of androgen receptor. 39 In the present study, we found that swapping the CMV promoter for ARR 2 PB shifted the apparent 50% viability in LNCaP cells from approximately 0.01 to 0.2-0.5 mM GCV, in keeping with the substantially weaker gene promoter activity associated with ARR 2 PB. 5 However, despite this difference in magnitude, the presence or absence of the UTR had no effect on the pattern of response to increasing concentrations of GCV in LNCaP cells nor on its intrinsic prostatespecific expression (Figure 7 ).
Together our results indicate that the lentiviral vector, Lv-ARR 2 PB-UTK, incorporates genetic elements that enable both prostate-and tumor-specific cell killing and as such may serve as the basis for development of an ideal gene therapeutic which can effectively treat prostate cancer cells with minimal co-morbidity to normal tissues.
